Maughan, Benjamin L.

Enhancing Triage Efficiency and Accuracy in Emergency Rooms for Patients with Metastatic Prostate Cancer: A Retrospective Analysis of Artificial Intelligence-Assisted Triage Using ChatGPT 4.0

Gebrael, G., Sahu, K. K., Chigarira, B., Tripathi, N., Mathew Thomas, V., Sayegh, N., Maughan, B. L., Agarwal, N., Swami, U., & Li, H. (2023) · Cancers

Artificial Intelligence in Healthcare and EducationEmergency and Acute Care Studies

Cited by 85

Macrophage HIF-1α Is an Independent Prognostic Indicator in Kidney Cancer

Cowman, S. J., Fuja, D. G., Liu, X.-D., Tidwell, R. S. S., Kandula, N., Sirohi, D., Agarwal, A. M., Emerson, L. L., Tripp, S. R., Mohlman, J. S., et al. (2020) · Clinical Cancer Research

Renal cell carcinoma treatmentCancer, Hypoxia, and Metabolism

Cited by 76

Belzutifan for von Hippel-Lindau disease-associated renal cell carcinoma and other neoplasms (LITESPARK-004): 50 months follow-up from a single-arm, phase 2 study

Srinivasan, R., Iliopoulos, O., Beckermann, K. E., Narayan, V., Maughan, B. L., Oudard, S., Else, T., Maranchie, J. K., Iversen, A. B., Cornell, J., et al. (2025) · The Lancet Oncology

Renal cell carcinoma treatmentCancer, Hypoxia, and Metabolism

Cited by 50

Trends and Disparities in Next-Generation Sequencing in Metastatic Prostate and Urothelial Cancers

Hage Chehade, C., Jo, Y., Gebrael, G., Tripathi, N., Sayegh, N., Chigarira, B., Mathew Thomas, V., Galarza Fortuna, G., Narang, A., Campbell, P., et al. (2024) · JAMA Network Open

Prostate Cancer Treatment and ResearchCancer Genomics and Diagnostics

Cited by 44

Phase II Study of the Oral HIF-2α Inhibitor MK-6482 for Von Hippel-Lindau Disease-Associated Renal Cell Carcinoma

Jonasch, E., Donskov, F., Iliopoulos, O., Rathmell, W. K., Narayan, V., Maughan, B. L., Oudard, S., Else, T., Maranchie, J. K., Welsh, S. J., et al. (2020) · Journal of Clinical Oncology

Renal cell carcinoma treatmentCancer, Hypoxia, and Metabolism

Cited by 42

Phase 2 study of belzutifan (MK-6482), an oral hypoxia-inducible factor 2α (HIF-2α) inhibitor, for Von Hippel-Lindau (VHL) disease-associated clear cell renal cell carcinoma (ccRCC).

Srinivasan, R., Donskov, F., Iliopoulos, O., Rathmell, W. K., Narayan, V., Maughan, B. L., Oudard, S., Else, T., Maranchie, J. K., Welsh, S. J., et al. (2021) · Journal of Clinical Oncology

Renal cell carcinoma treatmentCancer, Hypoxia, and Metabolism

Cited by 22

Enfortumab vedotin (EV) as monotherapy in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Results of stage I of a phase 2 trial.

Swami, U., Maughan, B. L., Boucher, K. M., Nordblad, B., Lloyd, J., Batten, J., Phunrab, T. K., Quertinmont, J., Kohli, M., Gupta, S., et al. (2024) · Journal of Clinical Oncology

Prostate Cancer Treatment and ResearchLung Cancer Treatments and Mutations

Cited by 9